7 completed, 6 terminated, 4 active not recruiting. 12 Phase 1, 6 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Terminated 4, Active not recruiting 1 |
| Phase 2 | 6 | Active not recruiting 3, Terminated 2, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow utomilumab: new trials by email Literature Review of utomilumab trials Research Report on utomilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Avelumab, Lorlatanib, Talazoparib - Advanced Malignancies, NSCLC | Phase 3 | Active not recruiting | Pfizer | 77 | 2021-09-29 | 2026-10-20 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel - Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | Terminated | Kite, A Gilead Company | 15 | 2018-11-20 | 2024-06-28 |
| Rituximab + Immunotherapy in Follicular Lymphoma Rituximab, Utomilumab, Avelumab - Follicular Lymphoma | Phase 1 | Terminated | Dana-Farber Cancer Institute | 24 | 2018-10-30 | 2025-02-06 |
| T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide - COL6A3 Positive, HLA-A*0201 Positive Cells Present | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 5 | 2018-09-04 | 2024-11-07 |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Vinorelbine, Trastuzumab, Avelumab - Breast Cancer | Phase 2 | Active not recruiting | Adrienne G. Waks | 100 | 2018-06-21 | 2026-07-20 |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 16 | 2018-06-08 | 2026-10-02 |
| Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Utomilumab, ISA101b - Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2018-04-04 | 2022-12-16 |
| Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer Cetuximab, Irinotecan Hydrochloride, Pharmacodynamic Study - Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 34 | 2017-12-27 | 2026-01-06 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Completed | George W. Sledge Jr. | 18 | 2017-10-30 | 2022-10-19 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
| Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | Pfizer | 29 | 2016-12-16 | 2020-12-17 |
| A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Avelumab, Utomilumab, PF-04518600 - Advanced Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 409 | 2015-11-09 | 2024-07-30 |
| A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors PF-05082566, KW-0761 - Advanced/Metastatic Solid Tumors | Phase 1 | Terminated | Pfizer | 24 | 2015-05-01 | 2019-02-27 |
| Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 PF-04518600, PF-04518600 plus PF-05082566 - Neoplasms | Phase 1 | Completed | Pfizer | 174 | 2015-04-23 | 2022-04-21 |
| A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) PF-05082566, MK-3475 - Advanced Solid Tumors | Phase 1 | Completed | Pfizer | 23 | 2014-08-01 | 2019-02-08 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab PF-05082566, rituximab - Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 1 | Completed | Pfizer | 190 | 2011-06-21 | 2020-03-17 |
Squamous Cell Carcinoma of Head and Neck (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Lymphoma, Large B-Cell, Diffuse (3) · Melanoma (3) · Carcinoma, Renal Cell (2) · Lymphoma, Follicular (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1)
Pfizer (7) · M.D. Anderson Cancer Center (4) · Adrienne G. Waks (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · George W. Sledge Jr. (1) · Kite, A Gilead Company (1) · Laura Huppert, MD, BA (1)
United States (17) · Australia (4) · France (4) · Japan (4) · Italy (3) · Poland (3) · United Kingdom (3) · Belgium (2) · Canada (2) · South Korea (2) · Spain (2) · Taiwan (2) · Denmark (1) · Hungary (1) · Israel (1)
Adrienne Waks, MD, PhD (1) · Amir A Jazaeri (1) · Aung Naing (1) · Bonnie S. Glisson, BS,MD (1) · Caron A. Jacobson, MD (1) · Dale R Shepard, MD, PhD (1) · David S Hong (1) · Elizabeth Budde (1) · Esra E Cohen, MD (1) · George Sledge, MD (1) · Laura Huppert, MD (1) · Michael J Pishvaian, MD, PhD (1)
PMID 29549159, PMID 31801624, PMID 32144134, PMID 34515338, PMID 34615725, PMID 34687398, PMID 36302562, PMID 37851072, PMID 40139261, PMID 41646361
2014 (1), 2015 (1), 2016 (1), 2023 (1), P30CA016672 (1)